APT Alpha PRO Tech (APT) Insider Trading, Ownership & Congress Trades
Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0000884269
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
18
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $40.3K priced
What the filings say about APT
Insiders, 180 days
-$361.3K net sold
3 sellers · 0% of sales under a 10b5-1 plan
Alpha PRO Tech insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ALPHA PRO TECH LTD insiders sold a net $361.3K of stock across 31 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.5% of the 1,284,603 shares held after it.
- 1 other insider sold within 30 days.
- 18 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Millar Donna sold about $35.1K of APT on Sep 28, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 18 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on May 12, 2026.
- The trade is 86.8% of the 25,281 shares held after it.
- 1 other insider sold within 30 days.
- 18 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MONTGOMERY CHARLES D sold about $110.6K of APT on Sep 28, 2026, the largest insider sale at the company since 2020; 1 other insider sold within 30 days and 18 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on May 14, 2026.
- The trade is 31.3% of the 19,768 shares held after it.
- 1 other insider sold within 30 days.
- 18 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Garcia David R sold about $34.4K of APT on May 15, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 18 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 16, 2024.
- The trade is 24.8% of the 19,768 shares held after it.
- 1 other insider sold within 30 days.
- 18 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Garcia David R sold about $28.8K of APT on May 14, 2026; 1 other insider sold within 30 days and 18 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 11, 2026.
- The trade is 6.6% of the 75,281 shares held after it.
- 1 other insider sold within 30 days.
- 18 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MONTGOMERY CHARLES D sold about $31.4K of APT on May 12, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 18 funds added in the latest 13F quarter.31 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$361.3K over 180 days
-$145.7K over 90 days · -$35.1K of it by a 10%+ holder
below 55% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
18 funds bought in last quarter
below 75% of Medical Devices
Revenue
+2.3% year over year
below 72% of Medical Devices
Margin
6.0% net margin
more than 76% of Medical Devices
Buybacks
$99.0K repurchased, FY to 2026-06-30
below 98% of Medical Devices
Short interest
0.6% of the float short (float per yahoo 2026-10-26) · 1.9 days to cover · settled 2026-09-30
below 79% of Medical Devices
What changed in the last 30 days
Sep 30Director MONTGOMERY CHARLES D sold $262.9K (6 trades, May 11 to Sep 28)
Sep 30Director Millar Donna sold $35.1K (Sep 28)
Watch APT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+17.5%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns APT: institutional holders (13F)
13F holdings, latest reported quarter
642,500 sh
$3.6M
561,572 sh
$3.2M
512,476 sh
$2.9M
278,687 sh
$1.6M
242,699 sh
$1.4M
Congress trades in APT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
APT planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
APT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Needham Aggressive Growth Fund
$3.6M position · as of 2026-06-30
0.1%
Ultra-Small Company Market Fund
$123.1K position · as of 2026-06-30
0.1%
Omni Small-Cap Value Fund
$219.9K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$166.2K position · as of 2026-06-30
0.0%
T. Rowe Price Extended Equity Market Index Fund
$89.9K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$11.8K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Lloyd Hoffman
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$970.9K
$919.2K
$553.1K
+10%
n/a
2024
$987.0K
$986.6K
$525.7K
+32%
n/a
2023
$1.2M
$1.2M
$685.7K
+32%
n/a
2022
$920.9K
$873.4K
$505.0K
-64%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $361.3K sold by insiders over 180 days, 18 funds added last quarter. Each figure is a federal filing, dated the day it went public.
APT financials
Revenue growth
+2.3%
XBRL, annual
Net margin
6.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$61.9M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM APT
| FY Dec 2025 | $59.1M |
| FY Dec 2024 | $57.8M |
| FY Dec 2023 | $61.2M |
| FY Dec 2022 | $62.0M |
| FY Dec 2021 | $68.6M |
| Jun 2026 | $18.7M |
| Mar 2026 | $14.6M |
| Dec 2025 | $13.9M |
| Sep 2025 | $14.8M |
| Jun 2025 | $16.7M |
| Mar 2025 | $13.8M |
| Dec 2024 | $13.8M |
| Sep 2024 | $14.3M |
At each fiscal year end
Single quarter
Net margin, TTM
+6.7%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM APT
| FY Dec 2025 | +5.9% |
| FY Dec 2024 | +6.7% |
| FY Dec 2023 | +6.9% |
| FY Dec 2022 | +5.3% |
| FY Dec 2021 | +9.8% |
| Jun 2026 | +9.8% |
| Mar 2026 | +4.8% |
| Dec 2025 | +4.8% |
| Sep 2025 | +6.6% |
| Jun 2025 | +7.5% |
| Mar 2025 | +4.4% |
| Dec 2024 | +5.9% |
| Sep 2024 | +6.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$5.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM APT
| FY Dec 2025 | $1.7M |
| FY Dec 2024 | $1.9M |
| FY Dec 2023 | $7.7M |
| FY Dec 2022 | $3.8M |
| FY Dec 2021 | -$3.0M |
| Jun 2026 | $2.1M |
| Mar 2026 | -$105.0K |
| Dec 2025 | $51.0K |
| Sep 2025 | $3.8M |
| Jun 2025 | $1.9M |
| Mar 2025 | -$4.1M |
| Dec 2024 | $970.0K |
| Sep 2024 | $3.2M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity APT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt APT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+6.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity APT
| FY Dec 2025 | +5.6% |
| FY Dec 2024 | +6.3% |
| FY Dec 2023 | +6.9% |
| FY Dec 2022 | +5.4% |
| FY Dec 2021 | +11.2% |
| Jun 2026 | +6.6% |
| Mar 2026 | +5.8% |
| Dec 2025 | +5.6% |
| Sep 2025 | +5.9% |
| Jun 2025 | +5.7% |
| Mar 2025 | +6.4% |
| Dec 2024 | +6.3% |
| Sep 2024 | +6.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+5.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets APT
| FY Dec 2025 | +4.7% |
| FY Dec 2024 | +5.5% |
| FY Dec 2023 | +6.3% |
| FY Dec 2022 | +5.0% |
| FY Dec 2021 | +10.0% |
| Jun 2026 | +5.6% |
| Mar 2026 | +4.9% |
| Dec 2025 | +4.7% |
| Sep 2025 | +5.0% |
| Jun 2025 | +4.9% |
| Mar 2025 | +5.4% |
| Dec 2024 | +5.5% |
| Sep 2024 | +6.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital APT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+6.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed APT
| FY Dec 2025 | +5.5% |
| FY Dec 2024 | +5.0% |
| FY Dec 2023 | +6.4% |
| FY Dec 2022 | +7.3% |
| FY Dec 2021 | +12.5% |
| Jun 2026 | +6.5% |
| Mar 2026 | +5.7% |
| Dec 2025 | +5.5% |
| Sep 2025 | +5.1% |
| Jun 2025 | +4.5% |
| Mar 2025 | +5.1% |
| Dec 2024 | +5.0% |
| Sep 2024 | +5.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
13.60x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing APT
| FY Dec 2025 | 13.45x |
| FY Dec 2024 | 15.11x |
| FY Dec 2023 | 14.69x |
| FY Dec 2022 | 15.46x |
| FY Dec 2021 | 11.94x |
| Jun 2026 | 14.05x |
| Mar 2026 | 13.06x |
| Dec 2025 | 13.45x |
| Sep 2025 | 14.09x |
| Jun 2025 | 14.21x |
| Mar 2025 | 13.89x |
| Dec 2024 | 15.11x |
| Sep 2024 | 15.41x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value APT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+10.5%
TTM free cash flow over market value at close 2026-10-27
FCF yield APT
| FY Dec 2025 | +3.8% |
| FY Dec 2024 | +3.3% |
| FY Dec 2023 | +12.4% |
| FY Dec 2022 | +7.5% |
| FY Dec 2021 | -3.8% |
| Jun 2026 | +10.2% |
| Mar 2026 | +12.6% |
| Dec 2025 | +3.8% |
| Sep 2025 | +5.3% |
| Jun 2025 | +3.9% |
| Mar 2025 | -1.7% |
| Dec 2024 | +3.3% |
| Sep 2024 | +6.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.64x
P/E over trailing EPS growth of 21%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing APT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.38x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.66x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 0.99x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $59.1M | $57.8M | $61.2M | $62.0M |
| Gross profit | $22.5M | $22.9M | $22.8M | $21.7M |
| Operating income | $3.8M | $3.4M | $4.1M | $4.7M |
| Net income | $3.5M | $3.9M | $4.2M | $3.3M |
| EPS (diluted) | 0.33 | 0.35 | 0.35 | 0.26 |
| Operating cash flow | $2.4M | $5.7M | $8.5M | $4.3M |
| Cash | $17.0M | $18.6M | $20.4M | $16.3M |
| Buybacks | $3.3M | $4.5M | $4.0M | $3.9M |
SEC XBRL, fiscal years, as known on 2026-10-28
APT Stock Sonar score 5/7 axes
Find similar shapesCompareAPT ranks highest on profitability (78th percentile) and risk and compliance (73rd), and lowest on insider conviction (22nd), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
APT filings, in plain words
Are Alpha PRO Tech insiders buying or selling APT?
In the 180 days to 2026-10-28, Alpha PRO Tech insiders were net sellers, a net $361.3K across purchases and sales reported on Form 4, by 3 sellers.
Read the full summary
In the 180 days to 2026-10-28, Alpha PRO Tech insiders were net sellers of APT, a net $361.3K across purchases and sales reported on Form 4 by 3 sellers. None of the 9 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
